OLMA

Olema Pharmaceuticals, Inc.

Price Chart

No historical data available

Latest Quote

$10.27

-0.52 (-4.82%)
Current Price
Previous Close $10.79
Open $10.69
Day High $10.77
Day Low $10.19
Volume 740,846
Fetched: 2026-08-30T21:13:19
Stock Information
Shares Outstanding 87.50M
Total Debt $3.66M
Cash Equivalents $461.07M
Net Income $-204.57M
Sector Healthcare
Industry Biotechnology
Market Cap $898.60M
EPS (TTM) $-2.12
Exchange NMS
🌐 Visit Website
Recent Price History
No history data available. Data will be fetched automatically.
About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

📰 Latest News
No news articles available at the moment. Check back later for updates on OLMA.
Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Total Expenses $178,698,000 $142,258,000 $104,961,000 $106,988,000
Other Income Expense $23,000 $102,000 $-19,000 $-27,000
Other Non Operating Income Expenses $23,000 $102,000 $-19,000 $-27,000
Net Non Operating Interest Income Expense $16,224,000 $12,682,000 $8,325,000 $2,228,000
Operating Expense $178,698,000 $142,258,000 $104,961,000 $106,988,000
General And Administrative Expense $21,001,000 $17,741,000 $18,821,000 $24,714,000
Interest Expense - - - -
Interest Expense Non Operating - - - -
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-162,451,000 $-129,474,000 $-96,655,000 $-104,787,000
Net Interest Income $16,224,000 $12,682,000 $8,325,000 $2,228,000
Interest Income $16,224,000 $12,682,000 $8,325,000 $2,228,000
Normalized Income $-162,451,000 $-129,474,000 $-96,655,000 $-104,787,000
Net Income From Continuing And Discontinued Operation $-162,451,000 $-129,474,000 $-96,655,000 $-104,787,000
Total Operating Income As Reported $-178,698,000 $-142,258,000 $-104,961,000 $-106,988,000
Net Income Common Stockholders $-162,451,000 $-129,474,000 $-96,655,000 $-104,787,000
Net Income $-162,451,000 $-129,474,000 $-96,655,000 $-104,787,000
Net Income Including Noncontrolling Interests $-162,451,000 $-129,474,000 $-96,655,000 $-104,787,000
Net Income Continuous Operations $-162,451,000 $-129,474,000 $-96,655,000 $-104,787,000
Pretax Income $-162,451,000 $-129,474,000 $-96,655,000 $-104,787,000
Interest Income Non Operating $16,224,000 $12,682,000 $8,325,000 $2,228,000
Operating Income $-178,698,000 $-142,258,000 $-104,961,000 $-106,988,000
Per Share
Diluted EPS $-1.87 $-2.20 $-2.14 $-2.62
Basic EPS $-1.87 $-2.20 $-2.14 $-2.62
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-178,208,000 $-141,865,000 $-104,584,000 $-106,631,000
Reconciled Depreciation $490,000 $393,000 $377,000 $357,000
EBITDA (Bullshit earnings) $-178,208,000 $-141,865,000 $-104,584,000 $-106,631,000
EBIT $-178,698,000 $-142,258,000 $-104,961,000 $-106,988,000
Diluted Average Shares $87,006,027 $58,743,522 $45,247,098 $39,995,460
Basic Average Shares $87,006,027 $58,743,522 $45,247,098 $39,995,460
Diluted NI Availto Com Stockholders $-162,451,000 $-129,474,000 $-96,655,000 $-104,787,000
Research And Development $157,697,000 $124,517,000 $86,140,000 $82,274,000
Selling General And Administration $21,001,000 $17,741,000 $18,821,000 $24,714,000
Other Gand A $21,001,000 $17,741,000 $18,821,000 $24,714,000
Otherunder Preferred Stock Dividend - - - -
Fetched: 2026-08-24
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $478,559,000 $408,964,000 $253,895,000 $197,546,000
Total Assets $533,430,000 $450,979,000 $276,945,000 $215,645,000
Total Non Current Assets $17,978,000 $12,506,000 $10,432,000 $6,746,000
Other Non Current Assets $892,000 $698,000 - $2,771,000
Non Current Prepaid Assets $15,666,000 $9,748,000 $7,173,000 $2,771,000
Current Assets $515,452,000 $438,473,000 $266,513,000 $208,899,000
Other Current Assets $1,586,000 $366,000 $1,681,000 $1,516,000
Prepaid Assets $4,373,000 $1,901,000 $2,352,000 $2,643,000
Receivables $4,056,000 $2,120,000 $673,000 $319,000
Taxes Receivable $919,000 $0 - -
Accrued Interest Receivable $3,137,000 $2,120,000 $673,000 $319,000
Cash Cash Equivalents And Short Term Investments $505,437,000 $434,086,000 $261,807,000 $204,421,000
Cash And Cash Equivalents $48,301,000 $139,480,000 $68,539,000 $23,702,000
Debt
Total Debt $4,193,000 $1,429,000 $2,417,000 $2,565,000
Long Term Debt And Capital Lease Obligation $3,069,000 $257,000 $1,429,000 $1,550,000
Long Term Debt $3,000,000 - - -
Current Debt And Capital Lease Obligation $1,124,000 $1,172,000 $988,000 $1,015,000
Liabilities
Total Liabilities Net Minority Interest $54,871,000 $42,015,000 $23,050,000 $18,099,000
Total Non Current Liabilities Net Minority Interest $3,069,000 $257,000 $1,429,000 $1,550,000
Current Liabilities $51,802,000 $41,758,000 $21,621,000 $16,549,000
Payables And Accrued Expenses $42,425,000 $34,925,000 $15,168,000 $10,934,000
Payables $9,253,000 $4,460,000 $2,771,000 $442,000
Accounts Payable $9,253,000 $4,460,000 $2,698,000 $374,000
Total Tax Payable - $41,000 $73,000 $68,000
Other Current Liabilities - - - $82,000
Equity
Common Stock Equity $478,559,000 $408,964,000 $253,895,000 $197,546,000
Total Equity Gross Minority Interest $478,559,000 $408,964,000 $253,895,000 $197,546,000
Stockholders Equity $478,559,000 $408,964,000 $253,895,000 $197,546,000
Gains Losses Not Affecting Retained Earnings $621,000 $143,000 $347,000 $-1,813,000
Other Equity Adjustments $621,000 $143,000 $347,000 $-1,813,000
Retained Earnings $-597,557,000 $-435,106,000 $-305,632,000 $-208,977,000
Other
Ordinary Shares Number $81,376,449 $74,312,608 $54,992,784 $40,287,097
Share Issued $81,376,449 $74,312,608 $55,097,118 $40,287,097
Tangible Book Value $478,559,000 $408,964,000 $253,895,000 $197,546,000
Invested Capital $481,559,000 $408,964,000 $253,895,000 $197,546,000
Working Capital $463,650,000 $396,715,000 $244,892,000 $192,350,000
Capital Lease Obligations $1,193,000 $1,429,000 $2,417,000 $2,565,000
Total Capitalization $481,559,000 $408,964,000 $253,895,000 $197,546,000
Additional Paid In Capital $1,075,487,000 $843,920,000 $559,176,000 $408,333,000
Capital Stock $8,000 $7,000 $4,000 $3,000
Common Stock $8,000 $7,000 $4,000 $3,000
Preferred Stock $0 $0 $0 $0
Long Term Capital Lease Obligation $69,000 $257,000 $1,429,000 $1,550,000
Current Capital Lease Obligation $1,124,000 $1,172,000 $988,000 $1,015,000
Pensionand Other Post Retirement Benefit Plans Current $8,253,000 $5,661,000 $5,465,000 $4,518,000
Current Accrued Expenses $33,172,000 $30,465,000 $12,397,000 $10,492,000
Net PPE $1,420,000 $2,060,000 $3,259,000 $3,975,000
Gross PPE $1,420,000 $2,060,000 $3,259,000 $3,975,000
Other Properties $1,420,000 $2,060,000 $3,259,000 $3,975,000
Other Short Term Investments $457,136,000 $294,606,000 $193,268,000 $180,719,000
Treasury Shares Number - - $104,334 -
Accumulated Depreciation - - - $-581,000
Machinery Furniture Equipment - - - $59,000
Fetched: 2026-08-24
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-146,716,000 $-104,510,000 $-83,727,000 $-82,428,000
Operating Activities
Operating Cash Flow $-146,716,000 $-104,351,000 $-83,727,000 $-82,065,000
Cash Flow From Continuing Operating Activities $-146,716,000 $-104,351,000 $-83,727,000 $-82,065,000
Operating Gains Losses - $9,000 $111,000 -
Investing Activities
Investing Cash Flow $-155,760,000 $-93,526,000 $-4,851,000 $91,479,000
Cash Flow From Continuing Investing Activities $-155,760,000 $-93,526,000 $-4,851,000 $91,479,000
Capital Expenditure - $-159,000 - $-363,000
Financing Activities
Issuance Of Capital Stock $205,390,000 $266,288,000 $129,736,000 $0
Financing Cash Flow $211,297,000 $268,818,000 $133,415,000 $476,000
Cash Flow From Continuing Financing Activities $211,297,000 $268,818,000 $133,415,000 $476,000
Net Other Financing Charges $-6,514,000 - - -
Net Common Stock Issuance $205,390,000 $266,288,000 $129,736,000 $0
Common Stock Issuance $205,390,000 $266,288,000 $129,736,000 $0
Repurchase Of Capital Stock - - - -
Net Preferred Stock Issuance - - - -
Preferred Stock Issuance - - - -
Other
Issuance Of Debt $3,000,000 $0 - -
End Cash Position $48,301,000 $139,480,000 $68,539,000 $23,702,000
Beginning Cash Position $139,480,000 $68,539,000 $23,702,000 $13,812,000
Changes In Cash $-91,179,000 $70,941,000 $44,837,000 $9,890,000
Proceeds From Stock Option Exercised $9,421,000 $2,530,000 $3,679,000 $476,000
Net Issuance Payments Of Debt $3,000,000 $0 - -
Net Long Term Debt Issuance $3,000,000 $0 - -
Long Term Debt Issuance $3,000,000 $0 - -
Net Investment Purchase And Sale $-155,760,000 $-93,367,000 $-4,865,000 $91,842,000
Sale Of Investment $344,962,000 $301,592,000 $250,760,000 $305,502,000
Purchase Of Investment $-500,722,000 $-394,959,000 $-255,625,000 $-213,660,000
Net PPE Purchase And Sale $0 $-159,000 $14,000 $-363,000
Purchase Of PPE $0 $-159,000 $0 $-363,000
Change In Working Capital $2,775,000 $9,164,000 $-589,000 $3,022,000
Change In Other Current Liabilities $9,740,000 $10,040,000 $1,717,000 $5,744,000
Change In Other Current Assets $-6,145,000 $-2,957,000 $-5,324,000 $-1,114,000
Change In Payables And Accrued Expense $4,598,000 $2,510,000 $2,324,000 $351,000
Change In Payable $4,598,000 $2,510,000 $2,324,000 $351,000
Change In Account Payable $4,598,000 $2,510,000 $2,324,000 $351,000
Change In Prepaid Assets $-5,418,000 $-429,000 $694,000 $-1,959,000
Other Non Cash Items $-5,116,000 $-7,025,000 $-4,227,000 $514,000
Stock Based Compensation $17,586,000 $22,582,000 $17,256,000 $18,829,000
Depreciation Amortization Depletion $490,000 $393,000 $377,000 $357,000
Depreciation And Amortization $490,000 $393,000 $377,000 $357,000
Gain Loss On Sale Of PPE $0 $9,000 $111,000 $0
Net Income From Continuing Operations $-162,451,000 $-129,474,000 $-96,655,000 $-104,787,000
Sale Of PPE - $0 $14,000 $0
Amortization Of Securities - - - $-787,000
Preferred Stock Payments - - - -
Fetched: 2026-08-24